Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CAREER FEATURE

First-quarter biotech job picture

A quarterly snapshot of job expansions, reductions and availability in the biotech and pharma sectors.

AstraZeneca is set to expand its presence in China by spearheading the creation of a new life sciences park in Wuxi, just west of Shanghai. The UK-based pharma joins Sweden’s BioVentureHub, the Skolkovo Foundation of Russia and the UK BioIndustry Association as founding partners of the International Life Science Innovation Park, which will be built by the Wuxi city government. The park will support AstraZeneca’s R&D efforts at its current China Commercial Innovation Center and provide multinational companies with laboratory space, equipment and support, as well as links to local universities and hospitals.

Three years after it paid almost $6 billion for Bay Area biotech Stemcentrx, a string of setbacks has AbbVie trying to stem its losses. The company has laid off 178 Stemcentrx employees after a halted phase 3 trial for Rova-T (rovalpituzumab tesirine) in December forced it to take a $4 billion write-off. In 2016, Stemcentrx had 240 employees.

Other companies that announced layoffs in the first quarter include Five Prime Therapeutics, which cut 41 (20%) from its research, pathology and manufacturing divisions; Aduro Biotech, which will reduce headcount by 37% after deprioritizing several programs, including its personalized live-attenuated, double-deleted Listeria monocytogenes (pLADD) immunotherapy, in order to extend its cash into 2022; Singapore-based Aslan Pharmaceuticals, which said in January that it will reduce its headcount by 30% and cut operating expenses by 50%; and, finally, Compugen, which will eliminate 35 positions, primarily from R&D. The company said the cuts will extend its cash runway through mid-2020 and allow an expansion study of COM701, a monoclonal antibody targeting poliovirus receptor–related immunoglobulin domain that is in phase 1 testing for solid tumors.

Advertised biotechnology and pharmaceutical sector jobs in the job databases tracked by Nature Biotechnology were slightly down in the first quarter of 2019 (Tables 1 and 2) compared with the previous quarter (Nat. Biotechnol. 37, 194, 2019).

Table 1 Who’s hiring? Advertised openings at the 25 largest biotech companies
Table 2 Advertised job openings at the ten largest pharma companies

Author information

Affiliations

Authors

Corresponding author

Correspondence to Michael Francisco.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Francisco, M. First-quarter biotech job picture. Nat Biotechnol 37, 569 (2019). https://doi.org/10.1038/s41587-019-0120-4

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing